Search academic texts

Information × Registration Number 0311U003739, 0109U000463 , R & D reports Title Investigation of the risk factors for appearance of immune inhibitors in patients with hemophilia and other coagulation disorders popup.stage_title Дослідити зв'язок зовнішніх факторів, пов'язаних з лікуванням, та частоти появи інгібітору Head Loginsky Volodymyr Eustakhovych, Registration Date 07-06-2011 Organization LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE popup.description2 Research object -503 patients (men) for hemophilia A, aged 1 to 75 years who were in hospital in the hematology department of the specialized children's hospital department, surgical care to patients with haemophilia at the five municipal hospital in Lviv or observed in the dispensary and methodological department of haemophilia and koahulopatiy SI "Institute of Blood Pathology and Transfusion Medicine of Ukraine AMS" (Lviv). Aim: To clarify the role of genetic (internal) and envirolment (external) risk factors in the developement of inhibitors in hemophilia patients and their pathogenic significance in the development of resistance to substitution therapy. The studies performed revealed that the major risk factor for the inhibitor is the severity of hemophilia, sporadic disease, "inhibitory" family history. It was found that the presence of the inhibitor in patients with hemophilia causes significantly increased mortality in these patients. The analysis of family history of hemophilia patients found that sporadic hemophilia caused by new mutations and inhibitory 'family history affects the appearance of the inhibitor in these patients. Found that in patients with hemophilia in the application as the first infusion whole blood and FFP the risk of inhibitor significantly increases, and the application of factor VIII concentrate significantly reduced. The highest frequency of inhibitor found in patients with hemophilia A with states that require the introduction of large doses of concentrates factor VIII(IX). Major surgery significantly increases the risk of inhibitor development. In 96,5% of patients with inhibitory form of hemophilia discovered markers of hepatitis C and in 52,5% - markers HBV-infection (anti-HBs), which are more often than in patients without inhibitor. In 46,3% of hemophilia patients with inhibitor showing simultaneously two or more viral markers. Product Description popup.authors Бужерак Н.Ф. Дзісь Р.П. Красівська В.В. Оборін О.М. Стасишин О.В. Тушницький О.М. popup.nrat_date 2020-04-02 Close